1. February 21st 2013. Location: 1789 Restaurant Washington DC
Speaker:
Benjamin Z. Leder, MD
Associate Professor of Medicine at Harvard Medical School Associate Physician and clinical investigator in the Endocrine Unit Massachusetts General Hospital
Title: “Combination Osteoporosis Therapies”
Educational Objectives:
Be familiar with the key issues in the evaluation of candidates for antiresorptive versus anabolic therapy
Understand the data (and its limits) regarding the comparative efficacy of teriparatide and antiresorptive agents
Be able to critically evaluate the data regarding the efficacy of teriparatide before, during, or after therapy with antiresorptive agents.
2. April 25, 2013. Location: Bistro Provence Bethesda
Speaker:
Michael McClung, MD, FACE, FACP
Director, Oregon Osteoporosis Center
Title: “Fracture Risk: Back to Clinical Judgment”
Educational objectives:
Critically evaluate and use multiple fracture risk assessment online tools
Set individualized goals of osteoporosis treatment, combining fracture risk and bone mineral density targets
Appreciate known risks and benefits of osteoporosis therapies
3. June 6th, 2013. Location: Assaggi Restaurant
6641 Old Dominion Dr, McLean, VA 22101
Speaker:
Gary E. Friedlaender, M.D.
Wayne O. Southwick Professor and Chair
Department of Orthopaedics
Title: “Bone Fracture Repair and Regeneration”
Educational objectives:
Review the molecules involved in bone regeneration and repair
Use recombinant growth factors to promote fracture repair and increase bone mass
Appreciate the importance of growth factors in bone tumor development
4. August 29, 2013. Location: Mrs K's Restaurant, Silver Spring, MD
Speaker:
Douglas C. Bauer, MD
University of California, San Francisco
Professor in Residence
Director, UCSF Division of General Internal Medicine Research Program
Director, UCSF CTSA Training Program
Co-Director, UCSF CTSA
Title: “Best Use of Bone Turnover Markers”
Educational Objectives:
Use periodic laboratory testing after initiation of therapy to assess compliance and effectiveness and improve treatment adherence
Recognize over suppression of bone turnover by laboratory testing and terminate antiresorptive medication when appropriate
Recommend anabolic treatment for osteoporosis based on available clinical and biochemical evidence
5. October 10, 2013. Rescheduled for 2014
Speaker:
Ego Seeman, MD, FRACP
Professor of Medicine
The University of Melbourne, Australia
Title: “Upcoming Challenges in Osteoporosis Diagnosis and Treatment”
Educational objectives:
Discuss the material and structural basis of bone strength and its decay
Classify fracture risk in patients with osteopenia
Select indications and recognize potential adverse effects for current and upcoming treatment alternatives (bisphosphonates, denosumab, odanocatib, antisclerostin antibody)
6. November 14th, 2013 Location: Nora Restaurant Washington DC
Speaker:
Felicia Cosman, MD
Helen Hayes Hospital
Director of the Clinical Research Center
Professor of Clinical Medicine at Columbia University
NOF Clinical Director since 1996
Title: "Is there a role for combination therapy?”
Educational objectives:
Overview studies assessing sequential antiresorptive and anabolic, or simultaneous antiresorptive and anabolic medications
Review differences in results where anabolic therapy is utilized as first line treatment (with or without concomitant antiresorptive treatment) compared with anabolic therapy after prior antiresorptive treatment
Compare outcomes of anabolic/antiresorptive combinations/sequences re: areal BMD by DXA, volumetric BMD by QCT, bone strength by Finite Element Modeling, and bone turnover markers